Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Ibudilast

Ibudilast

pharmaceutical raw materials
Ibudilast structure

Ibudilast 

structure
  • CAS No:

    50847-11-5

  • Formula:

    C14H18N2O

  • Chemical Name:

    Ibudilast

  • Synonyms:

    1-Propanone,2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-;Pyrazolo[1,5-a]pyridine,1-propanone deriv.;2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanone;2-Isopropyl-3-isobutyrylpyrazolo[1,5-a]pyridine;KC 404;Ibudilast;Ketas;3-Isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine;1-(2-Isopropylpyrazolo[1,5-a]pyridin-3-yl)-2-methylpropan-1-one;AV 411;Pinatos;2-Methyl-1-(2-propan-2-ylpyrazolo[1,5-a]pyridin-3-yl)propan-1-one

  • Categories:

    Active Pharmaceutical Ingredients  >  Antiallergic Drugs

Description

Ibudilast(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor which has been marketed for treating asthma.Target: PDEIbudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). The inhibition of platelet aggregation and vasodilatation by ibudilast may be due to synergistic elevation of intracellular cyclic nucleotides and release of nitric oxide (NO) or prostacyclin from endothelium, rath


Solid


Ibudilast is a pyrazolopyridine.|Ibudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS). Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan.|Ibudilast is an orally bioavailable inhibitor of cyclic nucleotide phosphodiesterase (PDE), mainly PDE-3, -4, -10, and -11, with anti-(neuro)inflammatory, vasorelaxant, bronchodilator, analgesic, neuroprotective and potential anti-tumor activities. Ibudilast (IBD) is able to cross the blood-brain barrier (BBB). Upon administration, IBD exerts its potential anti-tumor activity against glioblastoma multiforme (GBM) cells by inhibiting PDE-4 and the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF), which results in a decrease in MIF, its receptor CD74, and AKT expression, and attenuates the immunosuppressive properties of monocytic myeloid-derived suppressor cells (MDSCs) and reduces T-regulatory cells (Tregs). This causes GBM cell apoptosis and inhibits GBM cell proliferation. In addition, IBD reduces, through its inhibitory effect on various PDEs, the production of certain pro-inflammatory cytokines, such as interleukin-6 (IL-6), IL- 1beta, leukotriene B4, and tumor necrosis factor-alpha (TNF-a). IBD also upregulates the anti-inflammatory cytokine (IL-10), and promotes the production of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-4 (NT-4). It also blocks toll-like receptor-4 (TLR-4), inhibits nitric oxide (NO) synthesis and reduces the level of reactive oxygen species (ROS). It also prevents platelet aggregation, causes cerebral vasodilation, bronchial smooth muscle relaxation, and improves cerebral blood flow. In addition, IBD attenuates the PDE-mediated activation of glial cells and abrogates PDE-mediated neuroinflammation and neurodegeneration. MIF is secreted by cancer stem cells (CSCs) and is highly expressed within GBM and plays a key role in tumor cell proliferation. Co-expression of MIF and CD74 in GBM is associated with poor patient survival.

Ibudilast Basic Attributes

230.31

230.31

1806241-263-5

M0TTH61XC5

DTXSID7049007

C65876

R - Respiratory system

2933990090

Characteristics

34.4

3

white solid

1.1±0.1 g/cm3

53.5-54 °C

175°C/7.5mmHg(lit.)

1.571

DMSO: 28 mg/mL, soluble

2-8°C

LD50 i.v. in mice: 260 mg/kg (Irikura, 1973)

Safety Information

NONH for all modes of transport

3

22-36/37/38

26-36

UR0711200

Xn

P261-P305 + P351 + P338

H302-H315-H319-H335

|Warning|H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 39 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia

Drug Information

For the treatment of multiple sclerosis, asthma, and cerebrovascular disease.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)|Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)|Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. (See all compounds classified as Phosphodiesterase Inhibitors.)

19 hours

Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of [nitric oxide] synthesis and reduction in reactive oxygen species.

3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine

Ibudilast Use and Manufacturing

Uses

Inhibitors of phosphodiesterase 4 (PDE4), which catalyzes the hydrolysis of cAMP, have potential applications in a variety of diseases, including asthma. Ibudilast is an inhibitor of PDE4 (IC50 = 54-239 nM) that, at higher doses, also inhibits PDE3 and PDE5 (IC50 = 1,600-3,510 nM). Through this action, it suppresses the elaboration of mediators involved in asthma and inflammation.[Cayman Chemical]

Human drugs -> Rare disease (orphan)

Computed Properties

Molecular Weight:230.31
XLogP3:3
Hydrogen Bond Acceptor Count:2
Rotatable Bond Count:3
Exact Mass:230.141913202
Monoisotopic Mass:230.141913202
Topological Polar Surface Area:34.4
Heavy Atom Count:17
Complexity:288
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

It has an inhibitory effect on the contraction of airway smooth muscle of isolated animals caused by inflammatory mediators such as leukotriene D4 (LTD4) and platelet activating factor (PAF); it can relieve airway smooth muscle spasm of guinea pigs caused by inflammatory mediators, and can inhibit passive skin allergic reactions in experimental animals.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Weihai Huaxi Pharmaceutical Group Co., Ltd.

    China China
    Active
  • Gansu Haipunuo Ruichuang Pharmaceutical Co., Ltd.

    China China
    Active
  • Shenzhen Neptunus Pharmaceutical Co., Ltd.

    China China
    Active

Recommended Suppliers of Ibudilast

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.